{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:23:18Z","timestamp":1791897798692,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T00:00:00Z","timestamp":1402099200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00280-014-2498-5","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T04:26:32Z","timestamp":1402028792000},"page":"277-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":169,"title":["A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Hee Kyung","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Sym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Bok","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Myung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Kyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"issue":"3","key":"2498_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4143\/crt.2013.45.3.162","volume":"45","author":"KW Jung","year":"2013","unstructured":"Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS (2013) Survival of Korean adult cancer patients by stage at diagnosis, 2006\u20132010: national cancer registry study. Cancer Res Treat 45(3):162\u2013171. doi: 10.4143\/crt.2013.45.3.162","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2498_CR2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92\u201398. doi: 10.1056\/NEJMoa011954","journal-title":"N Engl J Med"},{"issue":"9267","key":"2498_CR3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","volume":"357","author":"V Georgoulias","year":"2001","unstructured":"Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357(9267):1478\u20131484. doi: 10.1016\/S0140-6736(00)04644-4","journal-title":"Lancet"},{"issue":"17","key":"2498_CR4","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO.2002.12.112","volume":"20","author":"P Kosmidis","year":"2002","unstructured":"Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20(17):3578\u20133585","journal-title":"J Clin Oncol"},{"issue":"4","key":"2498_CR5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdq445","volume":"22","author":"PA Kosmidis","year":"2011","unstructured":"Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, Dimopoulos MA, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S, Katirtzoglou N, Bakogiannis C, Syrigos KN (2011) Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 22(4):827\u2013834. doi: 10.1093\/annonc\/mdq445","journal-title":"Ann Oncol"},{"issue":"1","key":"2498_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/mdm430","volume":"1","author":"PA Kosmidis","year":"2008","unstructured":"Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 1(1):115\u2013122. doi: 10.1093\/annonc\/mdm430","journal-title":"Ann Oncol"},{"issue":"1","key":"2498_CR7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2008.02.001","volume":"62","author":"SH Park","year":"2008","unstructured":"Park SH, Hong J, Kim YS, Kim Y, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Park J, Cho EK, Shin DB, Lee JH (2008) Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Lung Cancer 62(1):72\u201377. doi: 10.1016\/j.lungcan.2008.02.001","journal-title":"Lung Cancer"},{"issue":"21","key":"2498_CR8","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.2003.03.195","volume":"21","author":"EF Smit","year":"2003","unstructured":"Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group\u2013EORTC 08975. J Clin Oncol 21(21):3909\u20133917. doi: 10.1200\/JCO.2003.03.195","journal-title":"J Clin Oncol"},{"issue":"13","key":"2498_CR9","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590\u20131598","journal-title":"Eur J Cancer"},{"issue":"11","key":"2498_CR10","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","volume":"10","author":"TY Kim","year":"2004","unstructured":"Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10(11):3708\u20133716. doi: 10.1158\/1078-0432.CCR-03-0655","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2498_CR11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","volume":"18","author":"DW Kim","year":"2007","unstructured":"Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, Park K, Lee MY, Heo DS (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18(12):2009\u20132014. doi: 10.1093\/annonc\/mdm374","journal-title":"Ann Oncol"},{"issue":"2","key":"2498_CR12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/annonc\/mdp315","volume":"21","author":"WT Lim","year":"2010","unstructured":"Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PC, Wong NS, Chowbay B (2010) Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 21(2):382\u2013388. doi: 10.1093\/annonc\/mdp315","journal-title":"Ann Oncol"},{"issue":"1","key":"2498_CR13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4143\/crt.2012.44.1.37","volume":"44","author":"ST Kim","year":"2012","unstructured":"Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Kim YH, Shin SW (2012) Chemotherapy in patients older than or equal to 75 years with advanced non-small cell lung cancer. Cancer Res Treat 44(1):37\u201342. doi: 10.4143\/crt.2012.44.1.37","journal-title":"Cancer Res Treat"},{"issue":"2","key":"2498_CR14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","volume":"108","author":"KS Lee","year":"2008","unstructured":"Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108(2):241\u2013250. doi: 10.1007\/s10549-007-9591-y","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2498_CR15","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s10637-011-9757-7","volume":"30","author":"JL Lee","year":"2012","unstructured":"Lee JL, Ahn JH, Park SH, Lim HY, Kwon JH, Ahn S, Song C, Hong JH, Kim CS, Ahn H (2012) Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs 30(5):1984\u20131990. doi: 10.1007\/s10637-011-9757-7","journal-title":"Invest New Drugs"},{"issue":"2","key":"2498_CR16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.lungcan.2012.03.020","volume":"77","author":"JH Park","year":"2012","unstructured":"Park JH, Lee SH, Keam B, Kim TM, Kim DW, Yang SC, Kim YW, Heo DS (2012) EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 77(2):433\u2013437. doi: 10.1016\/j.lungcan.2012.03.020","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2498-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2498-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2498-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T05:20:01Z","timestamp":1565500801000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2498-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,7]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2498"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2498-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,7]]}}}